Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Pimasertib

Home DrugsPimasertib

Investigational

Small Molecule

Pimasertib

Unknown Manufacturer

Pimasertib is under investigation in clinical trial NCT01378377 (Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus).

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Overview

Pimasertib is under investigation in clinical trial NCT01378377 (Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus).

Technical identifiers

Chemical Formula: C₁₅H₁₅FIN₃O₃
CAS Number: 1236699-92-5
UNII ID: 6ON9RK82AL

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

COMPOUNDS AND METHODS FOR IRON-DEPENDENT DRUG RELEASE
Applicant: TATARA THERAPEUTICS INCPriority: 2024
WO